Phase 2
Development Phase
0
Upcoming Catalysts
0
Historical Events
4
Regulatory Approvals
No Catalysts Found
No catalyst events have been recorded for this drug yet.
3 competitors in Parkinson's Disease
View Full LandscapeNo patent data available. Pre-approval drugs may not have Orange Book listings.
Entacapone Orion
Entacapone is indicated as an adjunct to standard preparations of levodopa / benserazide or levodopa / carbidopa for use in adult patients with Parkinson's disease and end-of-dose motor fluctuations, who cannot be stabilised on those combinations.
View on EMAEntacapone Teva
Entacapone is indicated as an adjunct to standard preparations of levodopa / benserazide or levodopa / carbidopa for use in adult patients with Parkinson's disease and end-of-dose motor fluctuations, who cannot be stabilised on those combinations.
View on EMAComtan
Entacapone is indicated as an adjunct to standard preparations of levodopa / benserazide or levodopa / carbidopa for use in adult patients with Parkinson's disease and end-of-dose motor fluctuations, who cannot be stabilised on those combinations.
View on EMAComtess
Entacapone is indicated as an adjunct to standard preparations of levodopa / benserazide or levodopa / carbidopa for use in patients with Parkinson's disease and end-of-dose motor fluctuations, who cannot be stabilised on those combinations.
View on EMALeukemia, Myeloid, Chronic
Kidney Failure
Idiopathic Pulmonary Fibrosis
Ankylosing Spondylitis
Chronic Myeloid Leukemia